EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease

Sarah G Aldous, Edward J Smith, Christian Landles iD, Georgina F Osborne iD, Maria Cañibano-Pico, Iulia M Nita, Jemima Phillips iD, Yongwei Zhang, Bo Jin, Marissa B Hirst, Caroline L Benn, Brian C Bond und 3 weitere

Brain · 03.05.2024 · 147 (5) · 1784-1798

DOI: 10.1093/brain/awae063 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 22.02.2024. Verfasst von Sarah G Aldous und 14 weiteren Autor:innen. Beteiligte Einrichtung: Huntington's Disease Centre, Department of Neurodegenerative Disease and UK Dementia Research Institute at UCL, Queen Square Institute of Neurology, …. Hauptthemen laut MEDLINE: Huntington Disease, Trinucleotide Repeat Expansion, Huntingtin Protein. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Huntington's disease mutation is a CAG repeat expansion in the huntingtin gene that results in an expanded polyglutamine tract in the huntingtin protein. The CAG repeat is unstable and expansions of hundreds of CAGs have been detected in Huntington's disease post-mortem brains. The age of disease onset can be predicted partially from the length of the CAG repeat as measured in blood. Onset age is also determined by genetic modifiers, which in six cases involve variation in DNA mismatch repair pathways genes. Knocking-out specific mismatch repair genes in mouse models of Huntington's disease prevents somatic CAG repeat expansion. Taken together, these results have led to the hypothesis that somatic CAG repeat expansion in Huntington's disease brains is required for pathogenesis. Therefore, the pathogenic repeat threshold in brain is longer than (CAG)40, as measured in blood, and is currently unknown. The mismatch repair gene MSH3 has become a major focus for therapeutic development, as unlike other mismatch repair genes, nullizygosity for MSH3 does not cause malignancies associated with mismatch repair deficiency. Potential treatments targeting MSH3 currently under development include gene therapy, biologics and small molecules, which will be assessed for efficacy in mouse models of Huntington's disease. The zQ175 knock-in model carries a mutation of approximately (CAG)185 and develops early molecular and pathological phenotypes that have been extensively characterized. Therefore, we crossed the mutant huntingtin allele onto heterozygous and homozygous Msh3 knockout backgrounds to determine the maximum benefit of targeting Msh3 in this model. Ablation of Msh3 prevented somatic expansion throughout the brain and periphery, and reduction of Msh3 by 50% decreased the rate of expansion. This had no effect on the deposition of huntingtin aggregation in the nuclei of striatal neurons, nor on the dysregulated striatal transcriptional profile. This contrasts with ablating Msh3 in knock-in models with shorter CAG repeat expansions. Therefore, further expansion of a (CAG)185 repeat in striatal neurons does not accelerate the onset of molecular and neuropathological phenotypes. It is striking that highly expanded CAG repeats of a similar size in humans cause disease onset before 2 years of age, indicating that somatic CAG repeat expansion in the brain is not required for pathogenesis. Given that the trajectory for somatic CAG expansion in the brains of Huntington's disease mutation carriers is unknown, our study underlines the importance of administering treatments targeting somatic instability as early as possible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Huntington DiseaseTrinucleotide Repeat ExpansionHuntingtin ProteinAnimalsHumansMiceMutS Homolog 3 ProteinDisease Models, AnimalNerve Tissue ProteinsBrain

Stichwörter der Autor:innen

Huntington’s diseaseMSH3genetic modifierspathogenic CAG repeat lengthsomatic CAG repeat instability

Substanzen

Huntingtin ProteinMutS Homolog 3 ProteinNerve Tissue ProteinsMSH3 protein, human

Autor:innen und Institutionen

  • Huntington's Disease Centre, Department of Neurodegenerative Disease and UK Dementia Research Institute at UCL, Queen Square Institute of Neurology, University College London, London WC1N 3BG, UK.
  • Department of Cell Biology, Albert Einstein College of Medicine, New York, NY 10461, USA.
  • Rancho BioSciences, San Diego, CA 92127, USA.
  • LoQus23 Therapeutics, Riverside, Babraham Research Campus, Cambridge, CB22 3AT, UK.
  • Prism Training and Consultancy Limited, St John's Innovation Centre, Cambridge, CB4 0WS, UK.

ORCID-Profile: Christian Landles, Georgina F Osborne, Jemima Phillips, Gillian P Bates

Förderung

  • Wellcome Trust
  • NIH HHS
  • NCI NIH HHS
  • Medical Research Council
  • CHDI Foundation
  • UK Dementia Research Institute
  • Dementia Research Institute Ltd
  • Alzheimer’s Society and Alzheimer’s Research UK

Zitieren

APA

Aldous, S. G., Smith, E. J., Landles, C., Osborne, G. F., Cañibano-Pico, M., Nita, I. M., Phillips, J., Zhang, Y., Jin, B., Hirst, M. B., Benn, C. L., Bond, B. C., Edelmann, W., Greene, J. R., & Bates, G. P. (2024). A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease. Brain, 147(5), 1784-1798. https://doi.org/10.1093/brain/awae063

Vancouver

Aldous SG, Smith EJ, Landles C, Osborne GF, Cañibano-Pico M, Nita IM, et al. A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease. Brain. 2024;147(5):1784-1798. doi:10.1093/brain/awae063

BibTeX
@article{Aldous2024,
  author = {Aldous, Sarah G and Smith, Edward J and Landles, Christian and Osborne, Georgina F and Cañibano-Pico, Maria and Nita, Iulia M and Phillips, Jemima and Zhang, Yongwei and Jin, Bo and Hirst, Marissa B and Benn, Caroline L and Bond, Brian C and Edelmann, Winfried and Greene, Jonathan R and Bates, Gillian P},
  title = {A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease},
  journal = {Brain},
  year = {2024},
  volume = {147},
  number = {5},
  pages = {1784--1798},
  doi = {10.1093/brain/awae063}
}
Kostenlos starten →